Skip to main content

Table 2 Baseline demographic data for all treatment groups: European data

From: Interleukin-6: a new therapeutic target

 

Treatment

 

Characteristics

2 mg/kg (n = 53)

4 mg/kg (n = 54)

8 mg/kg (n = 52)

2 mg/kg + MTX (n = 52)

4 mg/kg + MTX (n = 49)

8 mg/kg + MTX (n = 50)

MTX (n = 49)

All groups (n = 359)

Age (years)

52.2

49.3

50.1

49.2

50.2

50.1

50.9

50.3

Sex (male/female)

9/44

13/41

14/38

7/45

12/37

11/39

11/38

77/282

Duration of RA (years)

9.19

9.79

9.21

9.33

7.82

10.62

11.24

-

TJC (28)

15

15

15

15

13

15

16

15

SJC (28)

11

11

12

11

11

11

12

11

ESR (mm/hour)

39a

41

39b

45c

40

39d

43

41

CRP (mg/l)

26a

19

22b

28c

31

24d

32

27

DAS28

6.48a

6.55

6.43b

6.58c

6.34

6.47d

6.75

 

RF positive (n)

44

39

43

46

38

40

47

 
  1. an = 52; bn = 51; cn = 50; dn = 49. CRP, C-reactive protein; DAS28, Disease Activity Score; ESR, erythrocyte sedimentation rate; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; SJC, swollen joint count; TJC, total joint count. Reproduced, with permission, from [13].
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us